肥胖的医疗管理:当前趋势和未来的前景
Andres Calderon Valladares1, Maria Aguilera Astudillo1, Alexsandra Rojas Drinnon1
1Houston Methodist Hospital, Houston, Texas, US.
Methodist DeBakey cardiovascular journal
|February 24, 2025
概括
肥胖影响超过70%的美国成年人,是心血管疾病的主要危险因素. 新的因克雷丁激动剂为减肥和改善心脏代谢健康提供了一个有希望的多目标方法.
科学领域:
- 内分泌学和代谢性疾病.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖和超重影响超过70%的美国成年人,由复杂的遗传,行为,环境和医疗因素驱动.
- 肥胖是心血管和代谢疾病的重要危险因素,需要有效的长期管理策略.
- 目前的治疗方案旨在减肥和改善心血管结果,解决食欲调节和热量消耗问题.
研究的目的:
- 审查目前针对肥胖的药理疗法.
- 探讨因克雷丁激动剂在管理肥胖和心脏代谢健康方面的新兴作用.
- 讨论肥胖的药理治疗的未来方向.
主要方法:
- 对肥胖的药理干预措施的文献综述.
- 针对食欲调节和新陈代谢的治疗机制的分析.
- 评估与减肥和心血管益处相关的临床结果.
主要成果:
- 从历史上看,药理疗法一直专注于中央食欲调节.
- 胰岛素激动剂代表了显著的进步,提供了多个目标的好处,包括减肥和血糖控制.
- 这些药物显示出降低心血管死亡率和改善整体代谢健康的潜力.
结论:
- 肥胖管理需要一种慢性护理方法,包括持续减肥和心脏代谢健康的策略.
- 胰岛素激动剂正在通过解决心脏代谢疾病的多个方面来改变肥胖治疗.
- 未来的研究应该继续探索和完善用于全面肥胖管理的药理学策略.
相关概念视频
Issues And Trends In Healthcare Delivery System
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...


